UCB (OTCMKTS:UCBJF) Shares Gap Up – Here’s What Happened

UCB SA (OTCMKTS:UCBJF) gapped up before the market opened on Friday . The stock had previously closed at $284.2414, but opened at $297.4480. UCB shares last traded at $297.4480, with a volume of 135 shares trading hands.

Analyst Upgrades and Downgrades

A number of brokerages have recently commented on UCBJF. The Goldman Sachs Group reaffirmed a “buy” rating on shares of UCB in a research report on Monday, February 16th. Wolfe Research started coverage on UCB in a research report on Monday, February 23rd. They set an “outperform” rating on the stock. Six investment analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, the company currently has a consensus rating of “Buy”.

UCB Stock Performance

The business has a fifty day moving average of $294.62 and a 200-day moving average of $297.44. The company has a debt-to-equity ratio of 0.33, a quick ratio of 0.78 and a current ratio of 1.19.

About UCB

UCB SA is a Belgium-based biopharmaceutical company focused on the discovery, development and commercialization of treatments for severe diseases of the immune system and the central nervous system. Founded in 1928 as Union Chimique Belge, the company transitioned from chemicals into pharmaceuticals and biologics and today concentrates its efforts on specialty medicines and research-driven innovation. UCB’s work spans small molecules and biologics, with an emphasis on improving outcomes for patients with chronic and complex conditions.

Key therapeutic areas for UCB include immunology and neurology, where the company markets several well-known products and maintains an active clinical pipeline.